secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mereo BioPharma Group plc (MREO)
CIK:        0001719714
Form:       8-K
Filed at:   2024-03-27T23:59:59+00:00
Accession:  0001193125-24-078800
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mereo BioPharma reports FY2023 revenue $10M, net loss $29.5M; cash $57.4M funds ops into 2026
--------------------------------------------------------------------------------

- Revenue $10.0M from Ultragenyx milestone and ReproNovo upfront; net loss $29.5M vs $42.2M in 2022.
- Cash $57.4M; net cash burn Q4 2023 $6.7M; expected runway into 2026 supporting current plans.
- Setrusumab Orbit (Phase 2/3) enrollment completes Q1 2024; Cosmic (Phase 3) H1 2024, by partner Ultragenyx.
- Alvelestat Phase 3 plan with partner around end 2024; FDA aligned on SGRQ primary endpoint.
- Leflutrozole licensed to ReproNovo for up to $64.25M milestones plus tiered mid-single digit royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/0001193125-24-078800-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1719714/000119312524078800/d807451d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-078800

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer